{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:47:29Z","timestamp":1794008849483,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113391","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:12:39Z","timestamp":1657631559000},"page":"113391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan"],"prefix":"10.1016","volume":"153","author":[{"given":"Grzegorz","family":"Grze\u015bk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Wo\u0142owiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rogowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Gilewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"Kowalkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Hertmanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Dobosiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113391_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.04.243","article-title":"Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden","volume":"175","author":"Thorvaldsen","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113391_bib3","first-page":"630","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"65","author":"Bahl","year":"2013","journal-title":"J. Am. Coll. Cardiol. HF Indian Heart J."},{"key":"10.1016\/j.biopha.2022.113391_bib4","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","article-title":"Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure","volume":"102","author":"Slawsky","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.113391_bib5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"Mehta","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113391_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2017.9973","article-title":"Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN Randomized Clinical Trial","volume":"318","author":"Cholley","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.113391_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/ehjcvp\/pvz065","article-title":"Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction","volume":"6","author":"Cosentino","year":"2020","journal-title":"Eur. Hear. J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113391_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.113391_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FJC.0000000000000636","article-title":"Use of levosimendan in intensive care unit settings: an opinion paper","volume":"73","author":"Herpain","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib10","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","article-title":"Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan","volume":"27","author":"Haikala","year":"1995","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.yjmcc.2016.02.003","article-title":"Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog","volume":"92","author":"Pineda-Sanabria","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.yjmcc.2010.08.019","article-title":"A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex","volume":"49","author":"Robertson","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/jmcc.1999.1093","article-title":"Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: Structure-response and binding analysis with analogs of levosimendan","volume":"32","author":"Levijoki","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib14","article-title":"A, Efficacy and safety of levosimendan and dobutamine in heart failure: a systematic review and meta-analysis","author":"i wsp. Jaguszewski","year":"2021","journal-title":"Cardiol. J."},{"key":"10.1016\/j.biopha.2022.113391_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1007878523663","article-title":"Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium","volume":"14","author":"Lochner","year":"2000","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.jvca.2008.01.024","article-title":"Levosimendan in aortic valve surgery: cardiac performance and recovery","volume":"22","author":"J\u00e4rvel\u00e4","year":"2008","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.biopha.2022.113391_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/1755-5922.12132","article-title":"Levosimendan improves hemodynamic status in critically Ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study","volume":"33","author":"Garc\u00eda-Gonz\u00e1lez","year":"2015","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib19","first-page":"281","article-title":"Use of levosimendan in critically ill patients with severe aortic stenosis and left ventricular dysfunction","volume":"1","author":"Caetano","year":"2012","journal-title":"Eur. Hear. J. Acute Cardiovasc. Care"},{"key":"10.1016\/j.biopha.2022.113391_bib20","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00465.2004","article-title":"Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure","volume":"288","author":"Tachibana","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2022.113391_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00005344-199705000-00001","article-title":"Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy","volume":"29","author":"Pagel","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib22","doi-asserted-by":"crossref","unstructured":"D. Burkhoff, S. Rich, P. Pollesello, Z. Papp, Levosimendan-induced venodilation is mediated by opening of potassium channels, (2021) 4454\u20134464.\u00a0\u3008https:\/\/doi.org\/10.1002\/ehf2.13669\u3009.","DOI":"10.1002\/ehf2.13669"},{"key":"10.1016\/j.biopha.2022.113391_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yjmcc.2014.07.007","article-title":"Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-\u03b1-induced cardiomyocyte death","volume":"75","author":"Yoshida","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1476-5381.2008.00024.x","article-title":"Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: Role for mitochondrial K ATP channel","volume":"156","author":"Grossini","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib25","doi-asserted-by":"crossref","unstructured":"A. Nowaczyk, M. Kowalska, J. Nowaczyk, G. Grze\u015bk, Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters, (2021).","DOI":"10.3390\/ijms22116029"},{"key":"10.1016\/j.biopha.2022.113391_bib26","doi-asserted-by":"crossref","unstructured":"G.Grze\u015bk, A. Nowaczyk, Current Modulation of Guanylate Cyclase Pathway Activity \u2014 Mechanism and Clinical Implications, (2021).","DOI":"10.3390\/molecules26113418"},{"key":"10.1016\/j.biopha.2022.113391_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1476-5381.1996.tb15716.x","article-title":"Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs","volume":"119","author":"Pagel","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bcp.2004.05.018","article-title":"Potassium-specific effects of levosimendan on heart mitochondria","volume":"68","author":"Kopustinskiene","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.amjcard.2005.07.018","article-title":"Cardioprotection: a new paradigm in the management of acute heart failure syndromes","volume":"96","author":"Maytin","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","article-title":"Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper","volume":"222","author":"Farmakis","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1399-6576.2009.02070.x","article-title":"Levosimendan cardioprotection in acutely \u03b2-1 adrenergic receptor blocked open chest pigs","volume":"54","author":"Metzsch","year":"2010","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.biopha.2022.113391_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2007.04.023","article-title":"Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure","volume":"197","author":"Parissis","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2022.113391_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH14-06-0549","article-title":"Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro","volume":"113","author":"Krychtiuk","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.biopha.2022.113391_bib34","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2006.06.052","article-title":"Effects of levosimendan on right ventricular function in patients with advanced heart failure","volume":"98","author":"Parissis","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2007.07.011","article-title":"Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure","volume":"195","author":"Parissis","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2022.113391_bib36","first-page":"1768","article-title":"Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure","volume":"92","author":"Parissis","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.biopha.2022.113391_bib37","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejheart.2006.03.003","article-title":"Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure","volume":"8","author":"Trikas","year":"2006","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.113391_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjcard.2005.03.092","article-title":"Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure","volume":"96","author":"Parissis","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00005344-199506261-00008","article-title":"Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure","volume":"26","author":"Sandell","year":"1995","journal-title":"J. Cardiovasc Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s002280000204","article-title":"Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin","volume":"56","author":"Antila","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib41","unstructured":"S. Sundberg, S. Antila, H. Scheinin, M. H\u00e4yh\u00e4, M. Virtanen, L. Lehtonen, Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals, Undefined (1998)."},{"key":"10.1016\/j.biopha.2022.113391_bib42","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/0091270004268319","article-title":"Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study","volume":"44","author":"P\u00f5der","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/clpt.1994.177","article-title":"Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers","volume":"56","author":"Lilleberg","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib44","unstructured":"S. Antila, A. J\u00e4rvinen, J. Akkila, T. Honkanen, M. Karlsson, L. Lehtonen, Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol, Arzneimittel-Forschung\/Drug Res., 47 (1997) 816\u2013820. \u3008https:\/\/europepmc.org\/article\/med\/9272237\u3009. (Accessed 15 April 2021)."},{"key":"10.1016\/j.biopha.2022.113391_bib45","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0091270007313390","article-title":"Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment","volume":"48","author":"Puttonen","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200746030-00004","article-title":"Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites","volume":"46","author":"Puttonen","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.113391_bib47","unstructured":"LEVO_Pharmacokinetics_JCP_1995.pdf, (n.d.)."},{"key":"10.1016\/j.biopha.2022.113391_bib48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5414\/CPP40465","article-title":"Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure","volume":"40","author":"Kivikko","year":"2002","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib49","first-page":"446","article-title":"The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan","volume":"36","author":"Antila","year":"1998","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","article-title":"Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure","volume":"9","author":"Lilleberg","year":"2007","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.113391_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1749-8090-5-9","article-title":"Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction","volume":"5","author":"Papadopoulos","year":"2010","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.biopha.2022.113391_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200746030-00004","article-title":"Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites","volume":"46","author":"Puttonen","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.113391_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0091270007313390","article-title":"Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment","volume":"48","author":"Puttonen","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejps.2004.07.005","article-title":"Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators","volume":"23","author":"Antila","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2022.113391_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0928-0987(99)00048-2","article-title":"Site dependent bioavailability and metabolism of levosimendan in dogs","volume":"9","author":"Antila","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2022.113391_bib56","first-page":"446","article-title":"The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan","volume":"36","author":"Antila","year":"1998","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/B:CARD.0000015860.08185.6d","article-title":"Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease","volume":"17","author":"P\u00f5der","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2022.113391_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/S1053-2498(99)00107-2","article-title":"Outpatient parenteral inotropic therapy for advanced heart failure","volume":"19","author":"Young","year":"2000","journal-title":"J. Heart Lung Transpl."},{"key":"10.1016\/j.biopha.2022.113391_bib59","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1388-9842(02)00041-7","article-title":"The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis","volume":"4","author":"Thackray","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.113391_bib60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2004.11.033","article-title":"Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone","volume":"95","author":"Nanas","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib61","first-page":"1768","article-title":"Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure","volume":"92","author":"Parissis","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.biopha.2022.113391_bib62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cardfail.2007.04.004","article-title":"A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure","volume":"13","author":"Mavrogeni","year":"2007","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.biopha.2022.113391_bib63","unstructured":"E.F. Papadopoulou, S.I. Mavrogeni, A. Dritsas, D.V. Cokkinos, Assessment of Quality of Life Using Three Activity Questionnaires in Heart Failure Patients After Monthly, Intermittent Administration of Levosimendan During a Six-Month Period, 2009."},{"key":"10.1016\/j.biopha.2022.113391_bib64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijcard.2011.03.013","article-title":"Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure","volume":"159","author":"Bonios","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib65","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","article-title":"Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival","volume":"60","author":"Malfatto","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113391_bib66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2015.08.188","article-title":"Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis","volume":"202","author":"Silvetti","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2022.113391_bib67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.113391_bib68","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"Suppl","key":"10.1016\/j.biopha.2022.113391_bib69","doi-asserted-by":"crossref","first-page":"L11","DOI":"10.1093\/eurheartj\/suy040","article-title":"Repetitive levosimendan treatment in the management of advanced heart failure","volume":"20","author":"Oliva","year":"2018","journal-title":"Eur. Hear. J."},{"key":"10.1016\/j.biopha.2022.113391_bib70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ehf2.12366","article-title":"Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period","volume":"6","author":"P\u00f6lzl","year":"2019","journal-title":"ESC Hear. Fail."},{"key":"10.1016\/j.biopha.2022.113391_bib71","unstructured":"Efficacy and Security of Intermittent Repeated Levosimendan Administration in Patients with Advanced Heart Failure: a Randomized, Double-blind, Placebo Controlled Multicenter Trial: LAICA Study., (n.d.). \u3008https:\/\/esc365.escardio.org\/Congress\/HEART-FAILURE-2016\/Late-Breaking-Trials-I-Focus-on-acute-heart-failure\/136186-efficacy-and-security-of-intermittent-repeated-levosimendan-administration-in-patients-with-advanced-heart-failure-a-randomized-double-blind-placebo-controlled-multicenter-trial-laica-study\u3009. (Accessed 26 April 2021)."},{"key":"10.1016\/j.biopha.2022.113391_bib72","unstructured":"W. Sinkiewicz Grzegorz Grze\u015bk, Ma.\u0142gorzata Dobosiewicz, Wojciech Hertmanowski, Joanna Banach, Danuta Karasek, Wojciech Gilewski, Robert Bujak, Jan B\u0142azejewski, Magdalena Weglarz, Dorota Bednarska, Magdalena Grochowska, JaroslawPietrzak, Anita Wozniak-Wisniewska, Kinga K., Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations, (2018) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03764\u3009."},{"key":"10.1016\/j.biopha.2022.113391_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.advms.2021.10.001","article-title":"Repetitive use of levosimendan in ambulatory heart failure patients (LEIA-HF) - the rationale and study design","volume":"67","author":"Tyci\u0144ska","year":"2022","journal-title":"Adv. Med. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222007806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222007806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:07:04Z","timestamp":1779970024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222007806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":73,"alternative-id":["S0753332222007806"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113391","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113391"}}